Engineered CHO cells as a novel AAV production platform for gene therapy delivery

被引:0
|
作者
Abdou Nagy
Lina Chakrabarti
James Kurasawa
Sri Hari Raju Mulagapati
Paul Devine
Jamy Therres
Zhongying Chen
Albert E. Schmelzer
机构
[1] AstraZeneca,Cell Culture and Fermentation Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D
[2] AstraZeneca,Biologics Engineering, R&D
[3] AstraZeneca,Analytical Science, Biopharmaceutical Development, Biopharma R&D
[4] AstraZeneca,Analytical Science, Biopharmaceutical Development, Biopharma R&D
[5] AstraZeneca,Clinical Pharmacology and Safety Sciences
来源
Scientific Reports | / 13卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The Herpes simplex virus (HSV)-based platform for production of recombinant adeno-associated viral vectors (rAAVs) yields higher titers and increased percentage of full capsids when compared to the triple transient transfection (TTT) method. However, this platform currently faces two major challenges. The first challenge is the reliance on commercial media, sometimes supplemented with serum, leading to costly manufacturing and a high risk for introduction of adventitious agents. The second challenge is that the production of HSV-1 relies on adherent complementing Vero cells (V27), making it difficult to scale up. We engineered serum-free-adapted CHO cells expressing key HSV-1 entry receptors, HVEM and/or Nectin-1 to address the first challenge. Using high-throughput cloning methods, we successfully selected a HVEM receptor-expressing clone (CHO–HV–C1) that yields 1.62 × 109, 2.51 × 109, and 4.07 × 109 viral genome copies/mL with rAAV6.2-GFP, rAAV8-GFP, and rAAV9-GFP vectors respectively, within 24 h post rHSV-1 co-infection. Moreover, CHO–HV–C1-derived rAAVs had comparable in vitro transduction, infectivity, and biodistribution titers to those produced by TTT. The second challenge was addressed via engineering CHO–HV–C1 cells to express HSV-1 CP27. These cells successfully produced rHSV-1 vectors, but with significantly lower titers than V27 cells. Taken together, the CHO/HSV system provides a novel, scalable, reduced cost, serum-free AAV manufacturing platform.
引用
收藏
相关论文
共 50 条
  • [1] Engineered CHO cells as a novel AAV production platform for gene therapy delivery
    Nagy, Abdou
    Chakrabarti, Lina
    Kurasawa, James
    Mulagapati, Sri Hari Raju
    Devine, Paul
    Therres, Jamy
    Chen, Zhongying
    Schmelzer, Albert E.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [2] Characterization of Novel AAV Vectors Engineered for Muscle Gene Delivery
    Green, Jennifer
    Golebiowski, Diane
    Willacy, Tiffany
    Huang, Guanrong
    Soustek-Kramer, Meghan
    Nguyen, Paul
    Anderson, Sara
    Hornakova, Alena
    McGonigle, Sharon
    Morris, Carl
    Pechan, Peter
    MOLECULAR THERAPY, 2020, 28 (04) : 247 - 247
  • [3] Rationally Engineered Novel AAV Capsids for Intraarticular Gene Delivery
    Li, Wenjun
    Samulski, R. Jude
    Li, Chengwen
    MOLECULAR THERAPY, 2023, 31 (04) : 651 - 652
  • [4] AAV-Exosomes: A Novel Platform for Myocardial Gene Delivery for Cardioprotection
    Adamiak, Marta
    Liang, Yaxuan
    Mathiyalagan, Prabhu
    Agarwal, Neha
    Kohlbrenner, Erik
    Jha, Divya
    Chepurko, Elena
    Jeong, Dongtak
    Ceholski, Delaine
    Dubois, Nicole
    Hajjar, Roger
    Sahoo, Susmita
    CIRCULATION RESEARCH, 2018, 123
  • [5] Rationally engineered novel AAV capsids for intra-articular gene delivery
    Li, Wenjun
    Feng, Susi Liu
    Herrschaft, Lizette
    Samulski, R. Jude
    Li, Chengwen
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (01)
  • [6] A novel platform for engineered AAV-based vaccines
    Babutzka, S.
    Zobel, L.
    Bogedein, J.
    Diedrichs-Moehring, M.
    Gehrke, M.
    Wildner, G.
    Ammer, H.
    Michalakis, S.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A210 - A210
  • [7] A novel platform for engineered AAV-based vaccines
    Babutzka, Sabrina
    Gehrke, Miranda
    Papadopoulou, Anastasia
    Diedrichs-Moehring, Maria
    Giannaki, Maria
    Hennis, Lena
    Foehr, Bastian
    Kooyman, Cale
    Osterman, Andreas
    Yannaki, Evangelia
    Wildner, Gerhild
    Ammer, Hermann
    Michalakis, Stylianos
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2025, 33 (01)
  • [8] Continued In Vitro and In Vivo Characterization of Novel AAV Vectors Engineered for Muscle Gene Delivery
    Green, Jennifer
    Willacy, Tiffany
    Boehler, Jessica
    Dhruva, Alina
    Meng, Hui
    Beatka, Margaret
    Ott, Emily
    Prom, Mariah
    Lawlor, Michael W.
    Pechan, Peter
    Morris, Carl
    MOLECULAR THERAPY, 2021, 29 (04) : 159 - 159
  • [9] Engineered human mesenchymal stem cells:: a novel platform for skeletal cell mediated gene therapy
    Turgeman, G
    Pittman, DD
    Müller, R
    Kurkalli, BG
    Zhou, SH
    Pelled, G
    Peyser, A
    Zilberman, Y
    Moutsatsos, IK
    Gazit, D
    JOURNAL OF GENE MEDICINE, 2001, 3 (03): : 240 - 251
  • [10] Towards an AAV Platform Production Media and Process for the Gene and Cell Therapy Community
    Ndahiro, Nelson
    Sargunas, Justin
    Wen, Junneng
    Betenbaugh, Michael
    McNally, David
    Brakewood, William
    MOLECULAR THERAPY, 2024, 32 (04) : 282 - 283